Enhanced weight loss effects of NT-0796 and semaglutide in combination ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Weight loss drugs can help people with obesity lose significant amounts of weight when other methods do not work.

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic ...

Dr. Bharti Shetye, also known as Dr. Abby, CEO and Physician Owner of Dr. Abby’s Weight Management Clinic, recently joined Gayle Guyardo, host of the global health and ...

Indian equities rebounded strongly, driven by a pause in US tariffs, with the Sensex gaining over 4%. Small caps surged, offering relief to investors after months of pressure. Banking stocks led the ...

Perhaps being able to save difficult matchups against division rivals for later in the season will allow the Giants to build enough of a cushion to sustain themselves through the trade deadline ...

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become household names in recent years, hailed as revolutionary treatments for type 2 diabetes and obesity.

This contrasts with the currently approved oral GLP-1 RA semaglutide (Rybelsus, Novo Nordisk), a peptide which ideally should be taken fasting and with no food or water for at least 30 minutes ...